These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25804992)

  • 1. Improved bioassays using a local effect, such as muscle paralysis, as an endpoint.
    Cevc G
    Toxicon; 2015 Jun; 99():89-94. PubMed ID: 25804992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.
    Broide RS; Rubino J; Nicholson GS; Ardila MC; Brown MS; Aoki KR; Francis J
    Toxicon; 2013 Sep; 71():18-24. PubMed ID: 23707612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice.
    Aoki KR
    Toxicon; 2001 Dec; 39(12):1815-20. PubMed ID: 11600142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN).
    Bigalke H; Rummel A
    Toxins (Basel); 2015 Nov; 7(12):4895-905. PubMed ID: 26610569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ouabain exacerbates botulinum neurotoxin-induced muscle paralysis via progression of muscle atrophy in mice.
    Fujikawa R; Muroi Y; Unno T; Ishii T
    J Toxicol Sci; 2010 Dec; 35(6):795-805. PubMed ID: 21139329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacodynamic comparison study of different botulinum toxin type A preparations.
    Kim SB; Ban B; Jung KS; Yang GH
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):150-4. PubMed ID: 23301818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C.
    Morbiato L; Carli L; Johnson EA; Montecucco C; Molgó J; Rossetto O
    Eur J Neurosci; 2007 May; 25(9):2697-704. PubMed ID: 17561839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.
    Roger Aoki K
    Toxicon; 2002 Jul; 40(7):923-8. PubMed ID: 12076646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity.
    Wyndaele JJ; Van Dromme SA
    Spinal Cord; 2002 Nov; 40(11):599-600. PubMed ID: 12411968
    [No Abstract]   [Full Text] [Related]  

  • 10. A substrate sensor chip to assay the enzymatic activity of Botulinum neurotoxin A.
    Lévêque C; Ferracci G; Maulet Y; Grand-Masson C; Blanchard MP; Seagar M; El Far O
    Biosens Bioelectron; 2013 Nov; 49():276-81. PubMed ID: 23787358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A.
    Hunt T; Clarke K
    Clin Neuropharmacol; 2009; 32(1):28-31. PubMed ID: 18978494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A microscale neuron and Schwann cell coculture model for increasing detection sensitivity of botulinum neurotoxin type A.
    Hong WS; Young EW; Tepp WH; Johnson EA; Beebe DJ
    Toxicol Sci; 2013 Jul; 134(1):64-72. PubMed ID: 23564642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Pharmacodynamics of Three Different Botulinum Toxin Type A Preparations following Repeated Intramuscular Administration in Mice.
    Byun J; Kwak S; Kwon JH; Shin M; Lee DK; Rhee CH; Kang WH; Oh JW; Cruz DJM
    Toxins (Basel); 2022 May; 14(6):. PubMed ID: 35737026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of modified botulinum neurotoxin A1 variants with a shorter persistence of paralysis and duration of action.
    Scheps D; López de la Paz M; Jurk M; Hofmann F; Frevert J
    Toxicon; 2017 Dec; 139():101-108. PubMed ID: 28918229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscle volume alterations in spastic muscles immediately following botulinum toxin type-A treatment in children with cerebral palsy.
    Williams SA; Reid S; Elliott C; Shipman P; Valentine J
    Dev Med Child Neurol; 2013 Sep; 55(9):813-20. PubMed ID: 23789782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination.
    Pellett S; Tepp WH; Toth SI; Johnson EA
    J Pharmacol Toxicol Methods; 2010; 61(3):304-10. PubMed ID: 20100585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of diffusion and duration of action of a new botulinum toxin type A formulation.
    Stone HF; Zhu Z; Thach TQ; Ruegg CL
    Toxicon; 2011 Aug; 58(2):159-67. PubMed ID: 21658400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BoNT/AB hybrid maintains similar duration of paresis as BoNT/A wild-type in murine running wheel assay.
    Kutschenko A; Reinert MC; Krez N; Liebetanz D; Rummel A
    Neurotoxicology; 2017 Mar; 59():1-8. PubMed ID: 28043867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Injection of high dose botulinum-toxin A leads to impaired skeletal muscle function and damage of the fibrilar and non-fibrilar structures.
    Pingel J; Nielsen MS; Lauridsen T; Rix K; Bech M; Alkjaer T; Andersen IT; Nielsen JB; Feidenhansl R
    Sci Rep; 2017 Nov; 7(1):14746. PubMed ID: 29116170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays.
    Rupp D; Nicholson G; Canty D; Wang J; Rhéaume C; Le L; Steward LE; Washburn M; Jacky BP; Broide RS; Philipp-Dormston WG; Brin MF; Brideau-Andersen A
    Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32545832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.